| Autor: |
Asmus E; Institute of Physiology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany., Karle W; Institute of Physiology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany., Brack MC; Department of Infectious Diseases and Respiratory Medicine, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany.; Division of Pulmonary Inflammation, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany., Wittig C; Institute of Physiology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany., Behrens F; Institute of Physiology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany.; Berlin Institute of Health (BIH), Berlin, Germany., Reinshagen L; DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany.; Department of Cardiology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany., Pfeiffer M; Department of Infectious Diseases and Respiratory Medicine, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany., Schulz S; Institute of Physiology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany., Mandzimba-Maloko B; Institute of Physiology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany., Erfinanda L; Institute of Physiology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany., Perret PL; Institute of Physiology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany.; Berlin Institute of Health (BIH), Berlin, Germany., Michalick L; Institute of Physiology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany.; DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany., Smeele PJ; Department of Pulmonary Diseases, Amsterdam UMC, VU University Medical Center, Amsterdam Cardiovascular Sciences (ACS), Amsterdam, The Netherlands., Lim EHT; Department of Intensive Care Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.; Department of Neurology, University of Amsterdam, Amsterdam UMC, Amsterdam Neuroscience, Amsterdam, The Netherlands., van den Brom CE; Department of Intensive Care Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.; Department of Anesthesiology, Amsterdam UMC, VU University Amsterdam, Amsterdam, The Netherlands., Vonk ABA; Department of Cardiothoracic Surgery, Amsterdam UMC, VU University Amsterdam, Amsterdam, The Netherlands., Kaiser T; German Rheumatism Research Centre Berlin (DRFZ) - Flow Cytometry Core Facility, Berlin, Germany., Suttorp N; Department of Infectious Diseases and Respiratory Medicine, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany.; German Center for Lung Research (DZL), Partner site Berlin, Berlin, Germany., Hippenstiel S; Department of Infectious Diseases and Respiratory Medicine, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany.; German Center for Lung Research (DZL), Partner site Berlin, Berlin, Germany., Sander LE; Department of Infectious Diseases and Respiratory Medicine, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany.; German Center for Lung Research (DZL), Partner site Berlin, Berlin, Germany., Kurth F; Department of Infectious Diseases and Respiratory Medicine, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany.; German Center for Lung Research (DZL), Partner site Berlin, Berlin, Germany., Rauch U; DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany.; Department of Cardiology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany., Landmesser U; Berlin Institute of Health (BIH), Berlin, Germany.; DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany.; Department of Cardiology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany., Haghikia A; Berlin Institute of Health (BIH), Berlin, Germany.; DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany.; Department of Cardiology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany., Preissner R; Institute of Physiology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany.; Science-IT, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany., Bogaard HJ; Department of Pulmonary Diseases, Amsterdam UMC, VU University Medical Center, Amsterdam Cardiovascular Sciences (ACS), Amsterdam, The Netherlands., Witzenrath M; Department of Infectious Diseases and Respiratory Medicine, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany.; Division of Pulmonary Inflammation, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany.; German Center for Lung Research (DZL), Partner site Berlin, Berlin, Germany., Kuebler WM; Institute of Physiology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany.; DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany.; German Center for Lung Research (DZL), Partner site Berlin, Berlin, Germany.; The Keenan Research Centre for Biomedical Science at St. Michael's, Toronto, ON, Canada.; Departments of Surgery and Physiology, University of Toronto, Toronto, ON, Canada.; These authors contributed equally to this work., Szulcek R; Institute of Physiology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany.; Department of Pulmonary Diseases, Amsterdam UMC, VU University Medical Center, Amsterdam Cardiovascular Sciences (ACS), Amsterdam, The Netherlands.; German Heart Center Berlin, Berlin, Germany.; These authors contributed equally to this work., Simmons S; Institute of Physiology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt Universität zu Berlin, Berlin, Germany szandor.simmons@charite.de.; DZHK (German Centre for Cardiovascular Research), partner site Berlin, Berlin, Germany.; These authors contributed equally to this work. |
| Abstrakt: |
Competing Interests: Conflict of interest: E. Asmus reports European patent application number EP22162072.7 (15 March 2022): CFTR Modulators for the treatment of vascular disease. F. Behrens reports a BIH-MD-TRENAL medical research student stipend and a visiting scientist grant from the German Centre for Cardiovascular Research (DZHK), as well as travel support from Berlin Institute of Health (BIH Biomedical Innovation Academy Mobility and Innovation Grant) and German Centre for Cardiovascular Research (DZHK Travel Grant). L. Erfinanda reports European patent application number 20196830.2 - 1112 (18 September 2020): New medical use of cystic fibrosis transmembrane conductance regulator (CFTR) modulators. P.L. Perret reports a travel grant from the German Centre for Cardiovascular Research (DZHK). L.E. Sander reports grants from the Federal Institute for Drugs and Medical Devices of Germany, the Federal Ministry of Research and Education (Germany), the Germany Research Foundation (DFG) and Miltenyi Biotech, and reports personal fees from GlaxoSmithKline, Novartis, Sanofi, Chiesi, Boehringer and Berlin Chemie. U. Rauch reports personal fees from Bayer Vital GmbH, Sanofi Aventis and Boehringer Ingelheim, and is an advisory board member of Bayer Vital GmbH, Sanofi Aventis and Boehringer Ingelheim; U. Rauch also has a leadership role at ESC. U. Landmesser reports personal fees from Abbott, Amgen Bayer, Cardiac Dimensions, Novartis, Pfizer, Novo Nordisk, Daiichi Sankyo, Sanofi, Boston Scientific, AstraZeneca and Boehringer Ingelheim. R. Preissner reports grants from the German Research Foundation (DFG) and European Patent application number EP22162072.7 (15 March 2022): CFTR modulators for the treatment of vascular disease. M. Witzenrath reports grants from the German Research Foundation (DFG), the Federal Ministry of Education and Research (Germany), the German Respiratory Society, the European Respiratory Society, the Marie Curie Foundation, the Else Kröner Fresenius Foundation, the Capnetz Foundation, the International Max Planck Research School, Actelion, Bayer Health Care, Biotest and Boehringer Ingelheim, reports personal fees from Noxxon, Pantherna, Vaxxilon, Aptarion, GlaxoSmithKline, Sinoxa, Biotest, AstraZeneca, Berlin Chemie, Chiesi, Novartis, Teva, Actelion, Boehringer Ingelheim and Bayer Health Care, and reports patents EPO 12181535.1: IL-27 for modulation of immune response in acute lung injury; WO/2010/094491: Means for inhibiting the expression of Ang-2; DE 102020116249.9: Camostat/Niclosamide cotreatment in SARS-CoV-2 infected human lung cells; and PCT/EP2021/075627: New medical use of cystic fibrosis transmembrane conductance regulator (CFTR) modulators. W.M. Kuebler reports grants from the German Research Foundation (DFG), the German Ministry for Research and Education (BMBF), and the German Centre for Cardiovascular Research (DZHK), and reports personal fees from Bayer AG, Germany, and reports European patent application number 20196830.2 - 1112 (18 September 2020): New medical use of cystic fibrosis transmembrane conductance regulator (CFTR) modulators; and European patent application number EP22162072.7 (15 March 2022): CFTR Modulators for the treatment of vascular disease; W.M. Kuebler is Chair-Elect, Publications Committee, American Physiological Society and President, German Society for Microcirculation and Vascular Biology. R. Szulcek reports European patent application number EP22162072.7 (15 March 2022): CFTR Modulators for the treatment of vascular disease. S. Simmons reports grants from the German Centre for Cardiovascular Research (DZHK) and the German Society for Heart Research, and reports European patent application number EP22162072.7 (15 March 2022): CFTR Modulators for the treatment of vascular disease. The remaining authors report no potential conflicts of interest. |
